Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ovarian Cancer Recurrent × Paclitaxel × Clear all

Phase

Status

Completed 2 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 48 Breast Neoplasms 37 Ovarian Neoplasms 34 Triple Negative Breast Neoplasms 22 Stomach Neoplasms 20 Endometrial Neoplasms 19 Squamous Cell Carcinoma of Head and Neck 18 Lung Neoplasms 17 Fallopian Tube Neoplasms 17 Esophageal Neoplasms 16 Neoplasms 14 Neoplasm Metastasis 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Esophageal Squamous Cell Carcinoma 13 Uterine Cervical Neoplasms 12 Carcinoma, Ovarian Epithelial 10 Head and Neck Neoplasms 7 Recurrence 6 Colorectal Neoplasms 6 Carcinoma 6 Melanoma 5 Carcinoma, Squamous Cell 5 Adenocarcinoma Of Esophagus 5 Adenocarcinoma 5 Uterine Neoplasms 4 Small Cell Lung Carcinoma 4 Oropharyngeal Neoplasms 4 Carcinoma, Transitional Cell 4 Peritoneal Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3

Interventions

liposomal doxorubicin 2 pembrolizumab 1 mirabegron 1 disitamab vedotin 1 anlotinib 1 Paclitaxel 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06843447 2026-03-27

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡